Insights

Articles

ISPOR 2020 WORKSHOP: Developing Global Indirect Treatment Comparison Programs for Market Access

DEVELOPING AND IMPLEMENTING AN INDIRECT TREATMENT COMPARISON (ITC) PROGRAM TO SUPPORT GLOBAL HEALTH TECHNOLOGY ASSESSMENT (HTA) AND REIMBURSEMENT SUBMISSIONS Virtual ISPOR 2020 | WEDNESDAY, May 20th, 2020 | 10:00 AM ET PURPOSE: This interactive workshop will examine…

Function Over Fashion: Implementing Value-Based Contracts Successfully

Public outcry over drug pricing, increased government scrutiny, and proposed exceptions to government pricing rules propelled the healthcare industry to move from volume to value-based contracting models. Known alternatively as innovative outcomes or risk-based agreements, value-based…

ISPOR 2020 PODIUM: PSM and Bayesian Hierarchical Design Methods to Integrate Single-Arm Studies into NMAs in Lung Cancer

APPLICATION OF PROPENSITY SCORE MATCHING AND BAYESIAN HIERARCHICAL DESIGN METHODS TO INTEGRATE SINGLE-ARM STUDIES INTO NETWORK META-ANALYSES (NMAS): Opportunities and Pitfalls Illustrated in a Case Study Assessing Ablation/Radiation Therapies in Lung Cancer Virtual ISPOR 2020 |…

ISPOR 2020 PODIUM: Methodological Challenges with NMAs Assessing Long-term Efficacy in Psoriasis

METHODOLOGICAL CHALLENGES WITH CONDUCTING NETWORK META-ANALYSES ASSESSING LONG-TERM COMPARATIVE EFFICACY IN PSORIASIS- A CRITIQUE OF ASSUMPTIONS UNDERPINNING RECENT INDIRECT TREATMENT COMPARISONS Virtual ISPOR 2020 | TUESDAY, May 19th, 2020 | 5:30-5:45 PM ET OBJECTIVES: In network meta-analysis…

ISPOR 2020 PANEL: Evidence Standards for Medical Device Adoption by U.S. Hospitals

ARE EXISTING REGULATORY EVIDENCE STANDARDS ADEQUATE FOR INFORMING DECISIONS ON MEDICAL DEVICE ADOPTION BY U.S. HEALTHCARE PROVIDERS/HOSPITALS? Virtual ISPOR 2020 | MONDAY, May 18th, 2020 | 11:00 AM ET MODERATOR: Nicole Ferko, MSC, EVERSANA ISSUE: With cost containment…

Proactive Steps to Ensure Appropriate Utilization of the First Disease-Modifying Therapy for Alzheimer Disease

Widespread hope exists that aducanumab will soon gain Food and Drug Administration approval as the first disease-modifying therapy for patients with mild cognitive impairment associated with Alzheimer disease (AD), which could significantly impact the management of…

Two Key Questions About Payer Strategies in 2020

In a PM360 Focus on Payer Strategies feature, Brian Davis addresses the question: Besides efforts to lower drug prices and increase transparency, what market access challenges/barriers will cause pharma companies the most stress this year? How…

PharmaVOICE Showcase on Connected Health and IoT

The Growing Potential of Connected IoT In PharmaVOICE’s Showcase on Connected Health and IoT, Ed Cox offers executive viewpoints on the challenges of integrating the Internet of Medical Things (IoMT) into pharma processes. “Breaking down siloes…

PharmaVOICE Outsourcing Showcase

The New Roaring 20s: How Outsourced Commercialization is the Revolution We Need. To effectively commercialize a product, traditional service silos stand in the way of true healthcare transformation. Do disparate service providers look at the life…

How COVID-19 Has Changed Payer Engagement Strategies

The healthcare industry is rightly focused on COVID-19 and its impact on patient care and allocation or utilization of healthcare resources. However, we cannot lose sight of our responsibility to provide appropriate therapeutic options for the…